SYNBIOTIC THERAPY INCREASES ERADICATION RATE IN HELICOBACTER PYLORI ERADICATION
[ X ]
Date
2013
Journal Title
Journal ISSN
Volume Title
Publisher
Carbone Editore
Access Rights
info:eu-repo/semantics/closedAccess
Abstract
Background: Probiotics are used in combinations of H. pylori eradication regimens with variable results. Many strains tested had shown positive effects on side effect profiles. However, a clear effect on eradication rate is studied thoroughly. We aimed to investigate the beneficial effect of a synbiotic combination in clarithromycin-based triple eradication therapy. Methods: Ninety-two patients who were infected with H. pylori (confirmed via endoscopic biopsy) were randomized into two groups: those undergoing standard triple treatment (control group (rabeprozol plus amoksisilin plus clarithromycin bid) n=49) and those receiving symbiotic (triple plus symbiotic bid group n=43). The symbiotic product contained lactobacillus, bifidobacterium and enterococcus. The 13C-breath test was performed at least 6 weeks after completing both therapy regimens. Results: In the synbiotic group, 3 of the patients complained of metallic taste (7.0%). 1 complained of diarrhea (23%), 3 had nausea (7.0%), 2 had gas (4.7%), 3 experienced vomiting (7.0%) and 1 had constipation (23%). In the control group, 3 of the patients experienced a metallic taste (63%), 7 had diarrhea (14.6%), 5 had nausea (10.4%), 3 had intestinal bloating (63%), 3 experienced vomiting (63%) and I had constipation (2.1%). There was no significant difference between the two groups. However, side effect intensity and eradication rates were significant different between the groups (p<0.05). The eradication rate in the synbiotic group was 88.4%, while it was 68.8% in the control group (p<0.05). Conclusion: The addition of synbiotic to triple therapy decreases the rate of antibiotic-related side effects. It also increases H. pylori eradication rates in clarithromycin-based triple therapy.
Description
Keywords
Helicobacter Pylori, Eradication, Probiotics, Synbiotics, Lactobacillus, Bifidobacteria
Journal or Series
Acta Medica Mediterranea
WoS Q Value
Q4
Scopus Q Value
Volume
29
Issue
3
